Sr. Scientist, Intellia Therapeutics, USA
*Corresponding Author: Raghu Vannam, Sr. Scientist, Intellia Therapeutics, USA.
Received: June 28, 2021; Published: January 31, 2022
The targeted protein degradation- proteolysis targeting chimeras (PROTAC) technology is an attractive strategy to evaluate the fast biology and changes in a target protein, and its degradation . The PROTAC- a hetero bi functional small molecule, one end contains a ligand of protein of interest (POI) and other end E3 ligase ligand attached through a linker, there by formation of a ternary complex resulted in ubiquitination of E3 ligase and ultimately tagging target proteins (POI) that then are recognized by the proteasome for degradation . PROTAC technology uses event driven process and catalytic mode of action, which is different than traditionally occupancy driven pathway and attracting from academia to industry.
Citation: Raghu Vannam. “Perspective on Targeted Protein Degradation strategy by PROTAC Technology". Acta Scientific Pharmaceutical Sciences 6.2 (2022): 18-19.
Copyright: © 2022 Raghu Vannam. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.